Search Results
AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, i...
IASC WCLC 2021: CX-2029 and AMG 757 for lung cancer
The DLL3-targeting BiTE, tarlatamab, for the treatment of SCLC
CD3EDG humanized mice: a powerful tool for advancing CD3 bispecifics preclinical evaluation
IASLC Webinar: World Conference on Lung Cancer 2020 Highlights
CECOG Immuno-Oncology and more HIGHLIGHTS 2021
What is the AMG 05 Clinical Trial?
Taking a BiTE Out of SCLC
How to Pronounce Tarlatans
2021 ASCO Direct Denver | Metastatic Lung Cancer Summary | Dr. Jose Pacheco
APCCC 2024 Day 3 - Session 7
Tumeurs thoraciques - L'ESMO 2021 décrypté par Gustave Roussy
